The Pneumococcal Polysaccharide-Tetanus Toxin Native C-Fragment Conjugate Vaccine: The Carrier Effect and Immunogenicity

Abstract EN

The encapsulated bacteria, as Streptococcus pneumonia, Haemophilus influenzae type b, and Neisseria meningitidis, cause serious morbidity and mortality worldwide.

The capsular polysaccharide (PS), which could elicit a weak T cell-independent immune response, is a vital virulence determinant.

One of the strategies to improve the PS-specific immunogenicity is to conjugate PS with a nontoxic carrier protein.

Tetanus toxoid (TT) and CRM197 are the typical carrier proteins for the PS conjugate vaccines.

TT is the inactivated tetanus toxin manipulated with formaldehyde, which suffers from the pollution from residual formaldehyde and the incomplete detoxification.

CRM197 has the disadvantage of low-yield purification with the requirement of sophisticated culture conditions.

Thus, a novel carrier protein without these disadvantages is highly required.

The tetanus toxin native C-fragment (Hc) is safe, low-cost, and highly immunogenic with easy purification, which can act as a promising carrier protein.

Pneumococcal serogroups 14 and 23F were major epidemic causes of pneumococcal infections.

In the present study, the capsular PSs (PS14 and PS23F) were conjugated with Hc, TT, and CRM197, respectively.

TT- and CRM197-based conjugates acted as controls for Hc-based conjugates (PS14-Hc and PS23F-Hc).

The structural properties of Hc were not fundamentally changed after conjugated with PS.

PS14-Hc and PS23F-Hc could potentiate sound PS-specific antibody levels comparable to the controls.

Thus, Hc exhibited a practical carrier effect to help the pneumococcal conjugate vaccines perform good immunogenicities.